Administration of Dexamethasone in PONV Prophylaxis in Children Undergoing Adenotomy
Primary Purpose
Nasal Obstruction, Nasopharyngeal Obstruction, Snoring
Status
Completed
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
Dexamethasone
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Nasal Obstruction
Eligibility Criteria
Inclusion Criteria:
- Age (3-15 years)
- Signed informed consent by legal representatives of the child and patients (depending on the patient's age)
- Patients indicated for surgical procedure: adenotomy
Exclusion Criteria:
- ASA III and more
- Chronic medication: corticosteroids
- Malignant disease
Sites / Locations
- University Hospital Ostrava
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dexamethasone
Placebo
Arm Description
Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
Outcomes
Primary Outcome Measures
PONV incidence
To determine, whether Dexamethasone administered in single prophylactic dose of 0.15mg/kg of body weight of the child, after general anaesthesia induction, statistically significantly decreases the incidence of PONV in paediatric patients at the age between 3 and 15 undergoing adenotomy
Secondary Outcome Measures
Nausea incidence
To assess the incidence of nausea in children using BARF score and monitoring of possible difference between the interventional and control groups
Full Information
NCT ID
NCT03398044
First Posted
January 5, 2018
Last Updated
June 4, 2019
Sponsor
University Hospital Ostrava
1. Study Identification
Unique Protocol Identification Number
NCT03398044
Brief Title
Administration of Dexamethasone in PONV Prophylaxis in Children Undergoing Adenotomy
Official Title
Administration of Dexamethasone in PONV Prophylaxis in Children Between 3 and 15 Years of Age Undergoing Adenotomy in General Anaesthesia; Risks and Side Effects of the Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
January 1, 2017 (Actual)
Primary Completion Date
December 31, 2018 (Actual)
Study Completion Date
March 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Ostrava
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Adenotomy, together with tonsillectomy, belongs among the most frequently performed surgical procedures in paediatric patients. These surgical procedures are associated with the second highest incidence of post-operative nausea and vomiting (PONV) (following strabism correction surgery) in paediatric surgery. PONV is associated, apart from the discomfort for the child, with a number of complications: dehydration, metabolic disruption or danger of haemorrhage and aspiration of the gastric content. Adenotomy is a typologically completely different surgical procedure, with a different target structure of the surgery, and the length and invasiveness of the procedure. Thus, it is possible to expect a difference in PONV incidence when compared to tonsillectomy. Adenotomy is a surgical procedure performed namely in children of the pre-school age. This is associated, among others, also with the problem of objectivization of post-operative nausea, which is very difficult to verbalize in small children, being a subjective feeling of body discomfort. It is possible to expect that the overall incidence of PONV will be significantly underestimated.
Detailed Description
Randomization The study subjects were randomized into two arms, using computer-generated sequence of binary code: interventional arm with dexamethasone administration and control group with a placebo - physiological solution. Anaesthesiology nurse, who was not a part of the research team, randomly selected a vial for each enrolled patient, which was later administered to the patient. The number of the ampule corresponded with the patient's number.
Standardized anaesthesiology protocol General anaesthesia was administered in every paediatric patient according to a standardized anaesthesiology protocol. Each subject received premedication with midazolam in the dose of 0.5 mg/kg of body weight, per orally, 45 minutes before the surgical procedure. Inhalation induction of general anaesthesia was initiated with Sevoflurane, the vaporizer was set to 8%, using the carrying mixture of gases O2/air in the 1:1 ratio. After induction of anaesthesia, peripheral venous line was secured, with subsequent administration of an opioid - Sufentanil in the dose of 0.2 uq/kg of body weight, together with the research drug in the dose of 0.15mg/kg of body weight, with the maximum dose of 4 mg administered intravenously. The airways were secured in accordance with standard procedures used at our centre - armed laryngeal mask. In case of any leakages, air leaks, or any other problems with the laryngeal mask, the airways were secured with orotracheal intubation and introduction of tamponade into hypopharynx. General anaesthesia was further maintained using Sevoflurane, towards the values of MAC 1.2-1.5. Fluid therapy was guided by the 4/2/1 ml/kg of body weight /hr. rule - using Ringer's solution. Each subject was given standard analgetization for the early post-operative period: Paracetamol in the dose of 15mg/kg of body weight i.v. in the course of 10 minutes of the surgical procedure. Standard monitoring was provided for every patient: ECG, measurement of blood pressure, saturation, capnometry, inspiration and expiration Sevoflurane concentrations. After the surgery, every patient was woken up from anaesthesia, the laryngeal mask was removed (extubation) with spontaneous ventilation, the patient was further transferred to PACU.
Data collection Anaesthesiology team (anaesthetist + nurse), who was responsible for administration of general anaesthesia according to the standardized protocol, and who was trained to perform the study according to the study protocol, recorded the data concerning Dexamethasone/Placebo administration into a special Case Report Form, containing identification and number of the study drug. The form was transferred together with the patient to PACU, where the occurrence of PONV was monitored and recorded, together with the first value of the BARF score, by a PACU nurse and the child's parent. The form concerning the incidence PONV at inpatient department was provided for the parent who was present at the bedside of the patient at all times, up to the child's discharge from the hospital - the parent noted the number of vomiting episodes and BARF score 8 hours after the surgery (late BARF score); the parent was further instructed to ask the child ever 2 hours about possible sickness. In case of vomiting, the time and number of vomiting episodes were recorded.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nasal Obstruction, Nasopharyngeal Obstruction, Snoring, Apnea, Obstructive, Hearing Loss, Otitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study subjects were randomised into two arms, one group with active treatment using dexamethasone, and the other arm of subjects receiving placebo.
Masking
ParticipantInvestigator
Masking Description
Masking was provided by a nurse not participating upon the research.
Allocation
Randomized
Enrollment
200 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone
Arm Type
Experimental
Arm Description
Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be administered to patients randomised into the control group arm.
Primary Outcome Measure Information:
Title
PONV incidence
Description
To determine, whether Dexamethasone administered in single prophylactic dose of 0.15mg/kg of body weight of the child, after general anaesthesia induction, statistically significantly decreases the incidence of PONV in paediatric patients at the age between 3 and 15 undergoing adenotomy
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Nausea incidence
Description
To assess the incidence of nausea in children using BARF score and monitoring of possible difference between the interventional and control groups
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age (3-15 years)
Signed informed consent by legal representatives of the child and patients (depending on the patient's age)
Patients indicated for surgical procedure: adenotomy
Exclusion Criteria:
ASA III and more
Chronic medication: corticosteroids
Malignant disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michal Frelich, MD
Organizational Affiliation
University Hospital Ostrava
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Ostrava
City
Ostrava
State/Province
Moravian-Silesian Region
ZIP/Postal Code
70852
Country
Czechia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Administration of Dexamethasone in PONV Prophylaxis in Children Undergoing Adenotomy
We'll reach out to this number within 24 hrs